Notices for publication in the OJ nº T-347/18 of Tribunal General de la Unión Europea, July 27, 2018

• Resolution Date: July 27, 2018
• Issuing Organization: Tribunal General de la Unión Europea
• Decision Number: T-347/18

Action brought on 1st of June 2018 - Laboratoire Pareva and Biotech3D v Commission

(Case T-347/18)

Language of the case: English

Parties

Applicants: Laboratoire Pareva (Saint Martin de Crau, France) and Biotech3D Ltd & Co. KG (Gampern, Austria) (represented by: K. Van Maldegem and S. Englebert, lawyers)

Defendant: European Commission

Form of order sought

declare the application admissible and well-founded ;

annul the European Commission’s Implementing Regulation (EU) 2018/613¹ of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 under Regulation 528/2012² (the "Contested Act") ; and

order the defendant to pay the costs of these proceedings.

Pleas in law and main arguments

In support of the action, the applicants rely on three pleas in law which are in essence identical or similar to those relied on in Case T-337/18, Laboratoire Pareva v Commission.

____________

[1] Commission Implementing Regulation (EU) 2018/613 of 20 April 2018 approving PHMB (1415; 4.7) as an existing active substance for use in biocidal products of product-types 2 and 4 (OJ 2018, L 102, p.1)

[2] Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of...